APA (7th ed.) Citation

Aghemo, A., Persico, M., D'Ambrosio, R., Andreoni, M., Villa, E., Bhagat, A., . . . Gasbarrini, A. (2023). Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study. PLoS ONE, 18(2), 1. https://doi.org/10.1371/journal.pone.0280165

Chicago Style (17th ed.) Citation

Aghemo, Alessio, et al. "Safety and Effectiveness of 8 Weeks of Glecaprevir/Pibrentasvir in Challenging HCV Patients: Italian Data from the CREST Study." PLoS ONE 18, no. 2 (2023): 1. https://doi.org/10.1371/journal.pone.0280165.

MLA (9th ed.) Citation

Aghemo, Alessio, et al. "Safety and Effectiveness of 8 Weeks of Glecaprevir/Pibrentasvir in Challenging HCV Patients: Italian Data from the CREST Study." PLoS ONE, vol. 18, no. 2, 2023, p. 1, https://doi.org/10.1371/journal.pone.0280165.